2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
47
Leukemia, Myeloid, Acute
25
Recurrence
21
Lymphoma, Large B-Cell, Diffuse
13
Sarcoma
9
Lymphoma
6
Neoplasms, Plasma Cell
5
Neoplasm Metastasis
5
Glioblastoma
5
Endometrial Neoplasms
5
Ovarian Neoplasms
4
Neurofibrosarcoma
4
Neoplasms
4
Melanoma
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Non-Hodgkin
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, Extranodal NK-T-Cell
3
Lymphoma, B-Cell
3
Liposarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Waldenstrom Macroglobulinemia
2
Thymoma
2
Sarcoma, Alveolar Soft Part
2
Rhabdoid Tumor
2
Interventions
Paclitaxel
13
pembrolizumab
8
Carboplatin
7
Surveys and Questionnaires
6
Cisplatin
6
Brachytherapy
5
Doxorubicin
4
Docetaxel
4
Pemetrexed
3
Hyperthermic Intraperitoneal Chemotherapy
3
Gemcitabine
3
FANG vaccine
3
Biopsy
3
osimertinib
2
olaparib
2
niraparib
2
durvalumab
2
adavosertib
2
Trastuzumab
2
Topotecan
2
Taxes
2
Standard of Care
2
Sentinel Lymph Node Biopsy
2
Saline Solution
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Nivolumab
2
Music Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
selinexor
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled